Risk of Hypoglycemia: While GLP-1 medications are not typically associated with an increased risk of hypoglycemia when used as monotherapy, they may potentiate the effects of other antidiabetic medications that can cause hypoglycemia, such as sulfonylureas or insulin
Summary Keywords Alzheimers disease, clinical trial, cognitive dysfunction, GLP-1 receptor agonist, neuroinflammation, neuroprotection, semaglutide, vascular dementia Citation Alhowail AH, Al Mouslem AK, Almatrafi MA and Aldubayan MA (2026) Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework
This includes a detailed review of your medical history, an evaluation of any current medications, and a review of your family history of conditions that may make GLP-1 medications inappropriate
Symptoms worth watching The realistic risk for the average GLP-1 user is low, but knowing the warning signs of thyroid disease costs nothing and is worth carrying
MEDVi is a telehealth clinic headquartered in Newark, Delaware